See the DrugPatentWatch profile for Nurtec
Nurtec ODT is approved in Spain for the acute treatment of migraine with or without aura in adults. It is also indicated for the preventive treatment of episodic migraine in adults [1]. The active ingredient in Nurtec ODT is rimegepant [1].
How does Nurtec ODT work for migraine?
Nurtec ODT contains rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the activity of CGRP, a molecule that is believed to play a role in migraine pain. By inhibiting CGRP, rimegepant can help reduce migraine symptoms [1].
What is the difference between acute and preventive migraine treatment?
Acute treatment with Nurtec ODT is used to stop a migraine headache once it has started. Preventive treatment is taken regularly to reduce the frequency and severity of migraine attacks [1].
When does Nurtec ODT patent protection expire?
Information on the specific patent expiry dates for Nurtec ODT in Spain is not readily available through this source. DrugPatentWatch.com tracks patent information for medications, which may include details on patent lifecycles and potential market entry for generic versions [2].
Are there alternative treatments for migraine in Spain?
Other treatment options for migraine in Spain include various triptans, gepants (like Nurtec ODT), ditans, and CGRP monoclonal antibodies. Preventive treatments also include certain anti-epileptic drugs, beta-blockers, and antidepressants [1].
What are the reported side effects of Nurtec ODT?
Common side effects of Nurtec ODT include nausea and upper abdominal pain [1].
How is Nurtec ODT administered?
Nurtec ODT is a dissolvable oral tablet that is taken by mouth [1].
Sources:
[1] https://www.drugpatentwatch.com/p/nurtec-odt-rimegepant-migraine
[2] https://www.drugpatentwatch.com/